MGI Tech Co., Ltd., (SHA: 688114) a China-based leader in gene sequencing, announced a strategic collaboration with Belgium’s OncoDNA, a company specializing in precision medicine for cancer and genetic diseases. The partnership integrates the OncoDEEP Kit’s comprehensive workflow—including sequencing, secondary analysis, and final interpretation of next-generation sequencing (NGS) data through the OncoKDM platform—into MGI sequencers. Financial terms of the agreement were not disclosed.
This collaboration allows for rapid and precise full-process NGS, targeting critical regions linked to significant phenotypes such as Tumor Mutational Burden (TMB), Microsatellite Instability (MSI), and Loss of Heterozygosity (LOH) in Tumor Suppressor Genes (TSGs). It also includes intron tiling for genes such as ALK, ROS1, RET, and MET-ex14, along with sub-telomeric Single Nucleotide Polymorphisms (SNPs) used in calculating Homologous Recombination Deficiency (HRD) as well as the TERT promoter. The compatibility of the OncoDEEP Kit with MGI sequencers enhances the accessibility of precision oncology technologies.- Flcube.com
